Name | MK-8998 |
---|---|
Synonyms | MFCD22572346 |
Description | MK-8998 is a potent and selective antagonist of the T-type calcium channel. |
---|---|
Related Catalog | |
In Vitro | MK-8998 is a potent and selective antagonist of the T-type calcium channel that is being investigated as a potential new therapy for the treatment of schizophrenia. Because MK-8998 does not block D2, 5HT2a, muscarinic, or histaminic receptors, it has the potential for a substantially improved side effect profile compared with currently available atypical antipsychotics[1]. |
In Vivo | MK-8998 is not effective in treating acutely psychotic inpatients with schizophrenia. There are no significant differences between either MK-8998 or olanzapine versus placebo at any time point. MK-8998 and olanzapine are generally well tolerated but are associated with a higher percentage of adverse events compared with placebo[1]. |
References |
Molecular Formula | C20H23F3N2O2 |
---|---|
Molecular Weight | 380.40 |